1. Spring 2015

2. This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements which are not strictly historical statements, including, without limitation, statements regarding the plans, objectives and future financial performance of ScripsAmerica, constitute forward-looking statements which involve risks and uncertainties. The Company’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including anticipated operating losses, uncertainties associated with research, development, testing and related regulatory approvals, unproven markets, future capital needs and uncertainty of additional financing, competition, uncertainties associated with intellectual property, complex manufacturing, high quality requirements, dependence on third-party manufacturers, suppliers and collaborators, lack of sales and marketing experience, loss of key personnel, uncertainties associated with market acceptance and adequacy of reimbursement, technological change, and government regulation. For a more detailed description of the risk factors associated with the Company, please refer to the Company’s periodic reports filed with the U.S. Securities and Exchange Commission from time to time, including its Annual Report on Form 10-K for the year ended December 31, 2013. Undue reliance should not be placed on any forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to update any forward-looking information contained in this presentation. Safe Harbor Statement

3.  A leading, vertically integrated provider of a range of specialty prescription and over the counter pharmaceuticals and medical supplies  Serving large and growing markets:  Specialty Pharmaceuticals & Medical Supplies  Rapid Growth, Improving Financial Performance, Projecting Q1 Profits:  Solid Balance Sheet/Minimal Debt ($4MM LOC w/Triumph Healthcare)  Exciting growth opportunities:  New Products  New Geographies  New Distributors/Manufacturers ScripsAmerica, Inc. Q1 15 (P) (in millions, except EPS) (3/31/2015) Revenues $ 9.60 Net Income $ 0.40 EPS $ -

4. Trading Snapshot SymbolSCRC ExchangeOTCBB Price (4/1/15) $0.12 Market Capitalization (4/1/15) ~ $17 MM 52- Week Range$0.08 - $0.22 Average Daily Volume500,000 Shares Outstanding/Authorized139MM/250MM Corporate HeadquartersTysons Corner, Virginia

5.  138,829,119Outstanding  37,000,000Held By Founders  17,000,000Restricted  40,000,000Held By Core Group Share Structure

6.  2010 Operations Commence  2010 – 2012Pharmaceutical distribution services (primarily McKesson)  Retail, hospitals, long-term care facilities and government and home care agencies  2013 McKesson squeezes margins, increases chargebacks ScripsAmerica  2013-2014ScripsAmerica Pivots to New Growth Strategy -Initial (majority) investment in Main Avenue Pharmacy New Strategy o Enter Specialty Pharmacy and Independent Pharmacy distribution markets o Adding other, complementary products ScripsAmerica : Eo A H L ScripsAmerica: Evolution of A Healthcare Leader

7. OP – M O One Platform – Multiple Opportunities ScripsAmerica Wholesale Rx Main Avenue Pharmacy Evolving Businesses PIMD Diabetic Supplies RapiMed 2014 Revenues @$29,000,000.00 Q1 2015 Revenues @$912,000.00 Established Operations Evolving Operations 750+ Patients Signed $200,000 Order Pending Physician Dispensing

8.  Estimated 1% - 5% of population cannot tolerate medications in standard formulas*  Specialty pharmacy industry growth drivers:  Shortages of mass-produced drugs  Increased awareness of compounding pharmacies and pharmaceutical applications  Physicians concerned about prescribing narcotic pain medication (e.g. Oxycontin, Vicodin, Hydrocodone) and are looking for alternative delivery systems  Customize Rx to patient needs  Compounding industry:  $5 billion in Annual Revenues “A growing number of doctors and patients will likely turn to compounding pharmacies to prepare medications with alternate doses and strengths”* *source: IBIS Worldwide T S P M The Specialty Pharmaceuticals Market

9.  Main Avenue Pharmacy acquired Feb. 14, 2014 (100% effective October 2014)  Offering a wide variety of specialty pharmaceutical products to treat pain, scars, wounds, vitamin deficiencies among others  FDA approved and licensed in 10 states  Additional states being added  Capacity of hundreds of compounding prescriptions/month  No manufacturing (subject to more restrictive regulations) ScripsAmerica’s ScripsAmerica’s Specialty Pharma Business

10.  Doctor writes prescription and sends to Pharmacy  Submitted for payment to Insurance Company/Third party payers  No Medicaid, Medicare  Prescription approved for payment, charge set by PBM  Order to compound transmitted to Main Avenue Pharmacy  Bill generated & sent to Insurer/3 rd Party Payer  Prescription sent FedEx to patient - who must sign return receipt  Total Payment Cycle Time: 35-40 days 2006 Pre-Approval Avoids Collection Risk

11.  83% reported significant reduction in their pain after using custom-compounded prescription pain creams  On average, survey respondents said the creams reduced their pain levels by more than half  Five percent of respondents say the creams completely eliminated their pain  38 % reported reducing other oral pain medications while using the creams  > 83 % of respondents said their pain had eased since starting their use of the non-opioid prescription creams  They reported an average reduction of 57 percent in their pain level after directly applying the creams to the site of their pain, for most recent 24-hour period  After 4 weeks, patients reported significant improvement in their physical and emotional quality of life  Six percent of the patients reported minor adverse effects - such as rashes. ScripsAmerica’s Case Study: Just One of ScripsAmerica’s Many Products The results demonstrate the ability of locally-applied prescription creams to deliver significant pain relief over time to many patients, without the need for patients to rely on opioids and other narcotics. The FDA, quoted in the New York Times, said prescription drugs account for about three-quarters of all drug overdose deaths in the United States, with the number of deaths from narcotic painkillers, or opioids, quadrupling since 1999.quoted in the New York Times A 2011 report in the journal Pain Medicine, estimated the total societal cost of prescription opioid abuse at $55.7 billion. Pain Medicine Source: Patient Outcomes Analytics (POA), a research organization, a survey assessing patients' experience with topical prescription pain creams and their impact on the use of other oral pain medications. POA implemented an Institutional Review Board (IRB) approved protocol to survey and assess patient outcomes. More than 100 million Americans suffer from chronic pain

12. SP G S Specialty Pharmaceuticals Growth Strategy  Expand Licensing to New States  Add Pharmacies with states not currently serving  Bring on Additional Marketing Partners  Introduce New Products

13.  RapiMed – Child Pain & Fever Relief tablets- Approval Pending  PIMD International  Physician Dispensing Program  Diabetic Medical Supplies O G P Other Growth Platforms

14. R O D T RapiMed Oral Delivery Technology  Rapid Release, Fast Dissolving Fever & Pain Relief Tablets  Over The Counter Product Manufactured in United States  Regulated dosage (80mg, 160mg) for children 2 – 11  Signed Contract with Distributor in China  $200,000 order pending- $60,000 Cost (Attractive Margins)  Oral Tablet that dissolves in 25-35 Seconds  Fruit Flavors-Wild Cherry, Wild Grape  Fast Absorption Into System

15.  Problem: Small chains/individual pharmacies unable to fill prescriptions for controlled substances  Product manufacturers impose minimum order quantities far beyond the needs of the smaller operations  Solution: A DEA and State licensed business that represents independent pharmacies  PIMD licensed by DEA and 14 states for wholesale distribution of Prescription drugs and OTC branded products  Off to good startRevenues Q1 2015$912,000 P PIMD International, LLC

16.  Doctor Credentialed by service  PIMD Supplies Inventory based on practice history  Dr writes Rx  Office bills PBM  Dr dispenses Rx  Patient receives Rx without having to go to pharmacy to pick up medication  3 out of 4 patients prefer to receive their medications during an office visit  3 million adverse drug events are attributed to miscommunication at the pharmacy  On average medical practices spend $30,000 annually to handle pharmacy call backs  An estimated 30% of all prescriptions go unfilled  Scrips  ScripsAmerica’s PDP program facilitates Physician Compliance  Actively Being Marketed - In Discussion with Several Doctors P D P Physician Dispensing Program Goal = 100 dispensing physicians by 12/31/15

17. Robert Schneiderman, CEO & Founder  Accomplished entrepreneur with proven track record building businesses and creating value for shareholders  CEO of one of Philadelphia’s leading recruitment firms for 32 years Jeffrey Andrews, CFO  Finance professional with extensive background creating value with public companies  CFO - Global Resource Corporation, Judge Information Management Solutions, and The Judge Group Other Key Executives Peter W. Megill, CPA, Corporate Controller25 years experience Chad Beene, National Sales Manager11 years experience Adam Brosius, Director Business Development15 years experience S E L T Strong, Experienced Leadership Team

18. Financial Results

19. Recent Results of Operations Significant Improvement (P) Preliminary results, subject to final audit

20. March 31, 2015 (Projected) March 31, 2014 (Actual) (3 months) Revenue$ 9,600,000$ 800,000 Operating Income * $ 1,001,000$ 612 Income (loss) from Operations$ 594,000($ 214,000) Net Income (loss) ** $ 407,000($1,213,000) * prior to shares issued for services ** due to NOL, no tax liability recognized First Quarter 2015 Profitable

21. Strong & Improving Financial Position December 31, 2014*December 31, 2013 * (000’s omitted) Cash$ 730$ 47 Receivables$ 2,679$ 1,089 Inventory$ 1,011$ - 0 - Total Current Assets$ 4,699$ 1,490 Total Assets$ 5,659$ 1,781 Line of Credit$ 653$ 99 Payables & Accruals$ 2,268$ 227 Purchase Order Financing$ -0 -$ 1,037 Deferred Revenue$ 225$ -0 - Total Current Liabilities$ 3,349$ 3,188 Preferred Stock$ 1,043 Total Equity/(Deficit)($ 0.1)($ 3,617) Total Liabilities & Stockholders Equity $ 5,659$ 1,781 * BALANCE SHEET EXCERPTS

22.  149 Shareholders of record  Preferred Convertible Debt  - $1MM-Held by Board Member, Convertible into 6MM shares @ $.175  Term Debt – $233,000, 9% due 9/2016. Holder: Board member  Convertible Debt: $616,000 convertible at $.175(3 individuals)  Unsecured Debt $300,000 due 12/2015 (2 individuals)  A/R Financing of $4,000,000 (Secured)  Significant tax loss carryforwards available CS Capital Structure 12/31/14 12/31/13 Working Capital$1.350 MM($1.698 MM)

23. ScripsAmerica – Summary

24.  Expand the Compounding Rx Business -Add new Pharmacies, Products and Formulations  Launch RapiMeds  Launch Physician Dispensing Program  Add New Formulations of the Oral Delivery Technology  Strategic Acquisitions  Eliminate Convertible Notes/Pay Off Unsecured Debt  Uplist to Major Exchange ScripsAmerica – S ScripsAmerica – Strategy Valuation * 2014 Multiple of (e) sales@0.60X *as of 3/13/15

25. www.scripsamerica.com Robert Schneiderman, CEO 800-957-7622 ext 101 bob@scripsamerica.com Jeffrey J. Andrews, CFO 800-957-7622 ext 102 Jeff@scripsamerica.com CONTACT INFORMATION